{"abstract":"National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the Patent Applications listed in the Summary Information section of this notice to GeneXion Oncology, Inc., located in New York, NY.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2017/06/01/2017-11241.html","cfr_references":[],"citation":"82 FR 25295","comment_url":null,"comments_close_on":"2017-07-03","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Center for Advancing Translational Sciences on or before July 3, 2017 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2017-11241","effective_on":null,"end_page":25295,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2017/06/01/2017-11241.xml","html_url":"https://www.federalregister.gov/documents/2017/06/01/2017-11241/prospective-grant-of-exclusive-patent-license-mutant-idh1-inhibitors-useful-for-treating-cancer","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2017-11241?publication_date=2017-06-01","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2017-06-01/2017-11241/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":139,"last_updated":"2026-06-28 10:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2017-06-01/pdf/2017-11241.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2017-11241.pdf?1496234730","publication_date":"2017-06-01","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2017/06/01/2017-11241.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T08:09:47Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":25295,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Mutant IDH1 Inhibitors Useful for Treating Cancer","toc_doc":"Mutant IDH1 Inhibitors Useful for Treating Cancer","toc_subject":"Exclusive Patent Licenses:","topics":[],"type":"Notice","volume":82}